Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404612 · ClinicalTrials.gov registry record · Phase 3
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
A Phase 3 study of Uveitis, Posterior and Uveitis, Intermediate, sponsored by Lux Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT00404612 is a Phase 3 study of Uveitis, Posterior and Uveitis, Intermediate that has completed, run by Lux Biosciences. The registered enrollment target is 218 participants, above the 124-participant average among 6 other Uveitis, Posterior trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT00404612, a Phase 3 study of Uveitis, Posterior and Uveitis, Intermediate, has completed, sponsored by Lux Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LX211
Study Locations (20)
Texas
- Texas Retina Associates - Arlington
- Retina Research Center - Austin
- Texas Retina Associates - Dallas
- Vitreoretinal Consultants - Houston
- Retina & Uveitis Consultants of Texas - San Antonio
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
- Massachusetts Eye Research and Surgery Institute - Cambridge
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Retinal Consultants of Arizona - Phoenix
Illinois
- University of Illinois - Chicago - Chicago
Indiana
- Midwest Eye Institute - Indianapolis
Maryland
- Wilmer Eye Institute - Baltimore
Michigan
- Associated Retinal Consultants, PC - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404612
The ClinicalTrials.gov registry entry for NCT00404612 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 6 other Uveitis, Posterior trials with a reported enrollment target (76% higher). The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Uveitis, Posterior appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00404612 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Massachusetts, Alabama.
Frequently Asked Questions
What is clinical trial NCT00404612 about?
NCT00404612 is a clinical study titled "A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis". The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
What is the current status of trial NCT00404612?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2007-01. Estimated completion is 2009-05.
What conditions does trial NCT00404612 study?
This clinical trial studies the following conditions: Uveitis, Posterior, Uveitis, Intermediate, Panuveitis.
What interventions are being tested in trial NCT00404612?
The interventions under investigation include: Placebo (DRUG), LX211 (DRUG).
Who is sponsoring clinical trial NCT00404612?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00404612 being conducted?
This trial has 20 study locations across Alabama, Arizona, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis, Posterior
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
ACTIVE NOT RECRUITING · Phase 3
-
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
COMPLETED · Phase 3
-
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
ACTIVE NOT RECRUITING · Phase 4
-
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
COMPLETED
-
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.